

Review Memo - August 5, 2009 - Hiberix

Department of Health & Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Manufacturing and Product Quality

To: 125347/0

From: Sean Byrd, Sr. Reg. Rev. Ofc., CBER/OCBQ/DMPQ/BI, HFM-675

Through: Carolyn Renshaw, Chief, CBER/OCBQ/DMPQ/BI, HFM-675

Applicant: GlaxoSmithKline Biologicals, License #1617

Product: *Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate) [Hiberix®]

Subject: Review Memo –, Original Application for *Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate). Indication: active immunization as a booster dose in toddlers for the prevention of invasive disease caused by *Haemophilus influenzae* type b.

ACTION DUE: 5 August 2009

RECOMMENDATIONS: I recommend approval based on the submitted information and the results of the inspection, and with the following Post Marketing Commitment:

- -----b(4)-----

BACKGROUND

GlaxoSmithKline Biologicals (GSK), submitted their original Biologics License Application for Hiberix® on 17 March 2009. The vaccine is indicated for booster immunization against invasive disease caused by *Haemophilus influenzae* type b (Hib). The Agency confirmed with GSK on 12 December 2008 that the application would receive priority review status due to current vaccine shortages.

Hiberix® is a lyophilized vaccine containing 10µg of purified polyribosyl-ribitol-phosphate capsular polysaccharide (PRP) of Hib, covalently bound to approximately 25µg of inactivated tetanus toxoid (manufactured by -----b(4)-----) with 12.6mg lactose (stabilizer). It is reconstituted at time of use with supplied diluent (0.9% NaCl) in a prefilled syringe. Diluent is manufactured by -----b(4)-----.

The following review covers the drug substance manufacture up to the final formulation of the bulk drug substance. Review of the manufacture of the drug product is covered in a separate document.

The table below shows the specifications for the Hib-TT bulk Conjugate which are aligned to the latest revision of the -----b(4)----- monograph for Haemophilus influenzae type b conjugate vaccines -----b(4)-----.

[b(4)]

Changes since Initial License in Other Countries

GSK states that since the original licensing of Hiberix® in Europe (1996) and other countries, several changes to its manufacture have been implemented. Below is a table describing the changes and their rationale.

[b(4)]

-----b(4)-----

-----.

8 Pages determined to be not releasable: b(4)

Control of Materials

-----b(4)-----:
-----b(4)-----

-----b(4)-----

[**b(4)**]

Control of Critical Steps

GSK states they classify in process controls as Quality Decision (QD) tests used to demonstrate the process is controlled and in Process Monitoring for process consistency evaluation and data accumulation for use during investigations. Consistency ranges have been established for both types of testing throughout the manufacturing process. Associated in process tests performed during manufacture are shown in their respective tables above. GSK states each test method has been validated and supporting data are provided in module 3.2.S.2.4 of the submission. Validation results appear acceptable.

Process Validation

GSK performed process validation to demonstrate consistency and determine critical operating parameters. They state process validation is achieved by demonstrating consistency through the manufacture of at least -b(4)- batches showing compliance with pre-established quality standards. Manufacturing of these batches must also show consistency of the unit-step performances, residuals clearance profiles, and manufacturing yields.

Process validation is accomplished by the identification of the manufacturing process critical parameters. All process control variables are categorized into critical or non-critical parameters according to GSK's process validation policy. Critical process parameters are either validated or, alternatively, the performance of the process unit step or module in which these critical parameters operate will be controlled on each produced batch in order to guarantee the unit-step robustness. GSK states a parameter is considered critical -----b(4)-----
-- ----- . Parameters not considered critical that exceed their operating range are analyzed for their effect on manufacturing consistency.

6 Pages determined to be not releasable: b(4)

----- b(4) -----

microorganisms). Depending on the intended use of the agent, the validation was conducted with interfering substances to show the presence of organic matter does not reduce the efficacy of the disinfectants. Agents were individually tested on -----b(4)----- (if applicable). --b(4)--- were contaminated with predefined microorganisms and tested before and after exposure. All agents were validated by --b(4)-- successive runs. Agents used include -----b(4)-----

Room cleaning procedures and frequency in -b(4)-are discussed in the EIR and shown here in tabular format. Sampling to demonstrate cleaning include -----b(4)----- for the floor, walls, doors, air in-takes, product contact equipment, mobile and fixed equipment, and airlocks. Organisms used in -b(4)- include -----b(4)-----
-----.

-----b(4)-----

[

b(4)

]

----b(4)-----

[

b(4)

]

-----b(4)-----

[

b(4)

]

Segregation of contaminated equipment and control of contamination are managed by material and personnel flows, equipment and facilities design; use of air locks; closed systems; HVAC; sanitizing agents; fumigation; cleaning and decontamination procedures; personnel gowning; and changeover procedures.

Critical operations are performed in Class -b(4)- dynamic -b(4)- in Class --b(4)-- surroundings. Production surfaces are smooth and hard with -b(4)- coated floors. Walls and ceilings are---b(4)----- coated with -----b(4)----- paint. Light fixtures, windows, doors and control panels are flush, minimizing potential for dust build-up. Shared facilities are designed for temporal, physical and operational segregation with separate access for personnel and materials; separate exit for product; dedicated personnel with access key cards; dedicated HVAC; dedicated WFI; dedicated decontamination stations; validated cleaning methods for shared equipment; dedicated wash rooms, storage rooms, and cold rooms.

-b(4)-. Acceptance criteria are the same as described above.

Steam Sterilization

Validation of the autoclaves used in the manufacture of Hiberix® was reviewed during the inspection. There were no objectionable issues noted. Please refer to the EIR for detailed discussions. Additional discussions are provided here.

In addition to the autoclaves used for the sterilization of equipment and parts used in production, there is also an autoclave used for decontamination. The IOQ were performed followed by the PQ. -----b(4)-----

. Results of the validation appear to demonstrate successful validation and the one deviation appears to have been satisfactorily addressed. All autoclaves are requalified - --b(4)--.

Additionally, there are -b(4)- stations dedicated to the -----b(4)- ----- --in facilities -----b(4)------. The IOQ was successfully completed. GSK states the PQ was based on the temperature measurement -----b(4)- ----- and on the associated --b(4)-- with a microbiological challenge. Acceptance criteria include a minimum ---b(4)----- for b(4) minutes for all probes; no BI survives, sterile filters pass integrity testing; and all cycle phases are respected. The run time for validation was reduced from b(4) minutes to b(4) minutes under worst case conditions (all tanks and associated piping were full). There were -b(4)- runs completed. Results of the validation appear to demonstrate successful cleaning and deviations appear to be satisfactorily addressed.

-----b(4)-----

b(4) is used to sterilize the -----b(4)----- and associated piping found in -b(4)- . Validation was reviewed during the inspection and no objectionable issues were noted. Please refer to the EIR for further discussions. Additional details are provided here.

Validations included a -b(4)- decrease in dwell time and reduction of -b(4)- in temperature and a biological challenge. All temperature probes were associated with a BI. Acceptance criteria include no BI survival, ---b(4)-----, all filters pass integrity testing, and pre- and post calibration of probes are compliant. Results of the validation demonstrated successful sterilization and deviations appear to be satisfactorily addressed.

Media Simulations: -b(4)-

Validation was reviewed during the inspection and no objectionable issues were noted. Please refer to the EIR for further discussions. Additional details are provided here.

Media used in validation must support growth as tested before and after the process. All samples collected must be negative for growth. The validation must simulate all controlled bioburden stages and aseptic stages of -b(4)- production using a growth medium of broad spectrum (generally, --b(4)-----). All the production sequences and operations must be respected. If using a closed system (--b(4)--),

samples tested for sterility are first held for --b(4)-- before being sent for testing. The validation must cover -b(4)- successive successful runs.

For the ----b(4)----- run is performed using the maximum time allowed for aseptic manipulations and -b(4)- additional reduced time runs. In worst case conditions stages that require a -b(4)-hold are changed to -b(4)-, there is an increase in the time of manipulations, for -b(4)- steps there is a maximum of a ---b(4)--- followed by a ---b(4)--- temperature. Processes validated include the -----b(4)-----; introduction of media to the ---b(4)-----; and the ----b(4)-----step.

Chromatographic Systems

There are b(4) columns used in the chromatography steps of Hiberix® manufacture. The IQ included functional tests for -----b(4)----- . The PQ required contamination with worst case process solution covering -----b(4)----- . The columns also require that they be ---b(4)--- free. Cleaning validation acceptance criteria are as described. Results of the validation data appear to be acceptable.

----b(4)--- *Systems*

Validation was performed to demonstrate the sanitization is effective and that the agent can be removed. Additionally, -----b(4)----- must be removed. Acceptance criteria include -----b(4)----- to the quantification limit of the dosage; ----b(4)----- are within specified limits. As before the worst case conditions for cleaning were employed, in that the dirty hold was -----b(4)----- step to keep from -----b(4)----- . Cleaning validation acceptance criteria are as described. Results of the validation data appear to be acceptable.

Validations for Building ----b(4)---GSK states that the facilities validations have been approved previously for the eight other U.S. licensed products manufactured in this building. The requalification and re-validation of these followed the same methods as described. Successfully requalified systems include -----b(4)-----

----- . Review of the results for each of these systems appears to show successful requalification and deviations were satisfactorily addressed.

COMMENTS:

Though I recommend approval of this file, -----b(5)-----

-----.